Is JUPITER NEUROSCIENCES, INC. (JUNS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.6% / 30% | 28.3% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 1.6% / 33% | 28.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 3.5% / 33% | 60.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.6% / 33% | 28.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 3.5% / 33% | 60.8% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -354.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$4M |
| Free Cash Flow | -$4M |
| Total Debt | $217,761 |
| Debt-to-Equity | 314.2 |
| Current Ratio | 0.6 |
| Total Assets | $6M |
Price & Trading
| Last Close | $0.35 |
| 50-Day MA | $0.56 |
| 200-Day MA | $1.17 |
| Avg Volume | 329K |
|
52-Week Range
$0.31
| |
About JUPITER NEUROSCIENCES, INC. (JUNS)
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is JUPITER NEUROSCIENCES, INC. (JUNS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), JUPITER NEUROSCIENCES, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is JUPITER NEUROSCIENCES, INC.'s debt ratio?
JUPITER NEUROSCIENCES, INC.'s debt ratio is 1.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.5%.
What are JUPITER NEUROSCIENCES, INC.'s key financial metrics?
JUPITER NEUROSCIENCES, INC. has a market capitalization of $12M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.